- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02729558
Local Radiotherapy Following Complete Resection of a Brain Metastasis
Postoperative Local Stereotactic Radiotherapy Versus Observation Following a Complete Resection of a Single Brain Metastasis
Objective: To improve local control following complete resection of a single brain metastasis using fractionated local stereotactic radiotherapy, whilst maintaining neurological functioning, neurocognition and quality of life.
Study design: Multicenter randomized phase III, with at least three high-volume Dutch centers participating in the trial. Stratification on primary tumor type and age.
Study population: Patients undergoing complete resection of a single brain metastasis, confirmed by an early (i.e. within 72 hours) postoperative contrast-enhanced MR scan.
Study intervention: Patients will be randomized between observation alone (standard arm) and local stereotactic radiotherapy in three fractions of 8 Gy to the surgical cavity (study arm).
Main study parameters: Primary objective: local control rate at 6 months. Secondary objectives: local control rate at 12 months, neurological functioning, freedom from clinical neurological progression, performance status, quality of life, toxicity, steroid use, neurocognition and overall survival.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Amsterdam, Netherlands, 1066CX
- Netherlands Cancer Institute - Antoni van Leeuwenhoek
-
Amsterdam, Netherlands, 1081HV
- VU University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age of 18 years or older.
- Radiologically confirmed complete resection of a single brain metastasis on a contrast-enhanced MRI within 72 h after resection.
- Primary solid tumor, excluding hematologic malignancy, germ cell tumor, small cell lung cancer.
- Stable extracranial tumor (primary tumor and/or systemic metastases) during the last three months with or without treatment or progressive extracranial tumor and/or systemic metastases for which effective treatment is available.
- World Health Organization (WHO) performance score 0-2.
- Ability to provide written informed consent.
Exclusion Criteria:
- Prior treatment for brain metastases (i.e. surgery, stereotactic radiotherapy or WBRT).
- Distant brain metastases or radiological findings on MRI suspected for leptomeningeal tumor spread on the postoperative MRI.
- Concurrent use of systemic therapy during local stereotactic radiotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: observation
Watchful waiting
|
|
Active Comparator: local stereotactic radiotherapy (SRT)
local SRT in three fractions of 8 Gy to the surgical cavity
|
local stereotactic radiotherapy in three fractions of 8 Gy to the surgical cavity
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
local control rate
Time Frame: at 6 months
|
as assessed on follow-up MRI scans
|
at 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decrease in neurocognitive test results using the Hopkins Verbal Learning Test Revised (HVLT-R), in full cohorts
Time Frame: baseline, at 3 months, 6 months and 12 months
|
Neurocognitive testing will be performed at baseline, at three, six and twelve months follow-up using the Hopkins Verbal Learning Test Revised (HVLT-R).
The HVLT-R is one of the components used to form the core set of cognitive tests recommended to use in oncology trials.
This test measures immediate memory span, provides a learning curve, measures both short-term and longer-term retention, and allows for a comparison between retrieval efficiency and learning.
This version includes 3 learning trials of a 12-word list, an interval of 20 minutes a delayed recall, and a recognition trial consisting of the target words interspersed with distractor words.
The score on the recognition trial is the total number of correct response.
This measure has adequate psychometric properties and 6 multiple forms.
|
baseline, at 3 months, 6 months and 12 months
|
Decrease in specified neurocognitive test results using the Trail Making A and B, in full cohorts
Time Frame: baseline, at 3 months, 6 months and 12 months
|
Neurocognitive testing will be performed at baseline, at three, six and twelve months follow-up using the Trail Making A and B. This test is one of the components used to form the core set of cognitive tests recommended to use in oncology trials.
This is a test of visual conceptual and visuomotor tracking.
It measures psychomotor speed and aspects of executive function.
It is given in two parts, A and B. The subject must first draw lines to connect consecutively numbered circles on one work sheet (part A) and then connect the same number of consecutively numbered and lettered circles on another worksheet by alternating between the two sequences (part B).
The subject is urged to connect the circles as fast as possible
|
baseline, at 3 months, 6 months and 12 months
|
Decrease in neurocognitive test results using the Controlled Oral Word Association (COWA), in full cohorts
Time Frame: baseline, at 3 months, 6 months and 12 months
|
Neurocognitive testing will be performed at baseline, at three, six and twelve months follow-up using the Controlled Oral Word Association (COWA).
The COWA is one of the components used to form the core set of cognitive tests recommended to use in oncology trials.
This test measures speeded verbal fluency and aspects of executive function.
In this test, subjects are asked to generate as many words as possible in 1 minute beginning with "B", "D," and "H".
It has two forms.
|
baseline, at 3 months, 6 months and 12 months
|
Decrease in neurocognitive test results using using the Wechsler Adult Intelligence Scale (WAIS) III Digit Span and WAIS III Digit Symbol, in full cohorts
Time Frame: baseline, at 3 months, 6 months and 12 months
|
Neurocognitive testing will be performed at baseline, at three, six and twelve months follow-up using the WAIS III Digit Span and WAIS III Digit Symbol. These added cognitive tests are also chosen based on their proven sensitivity to measure change in neuro-oncology patients. The subtest of the WAIS-III (Digit Span) involves forward and backward repetitions of series of digits and provides measures of concentration. This measure has adequate psychometric properties. The subtest of the WAIS III (Digit Symbol) involves a symbol substitution task that requires visual-motor coordination, motor persistence, and sustained attention. The test is used as a test for information processing speed. The task consists of pairing numbers to nonsense symbols as quickly as possible. |
baseline, at 3 months, 6 months and 12 months
|
Decrease in neurocognitive test results using the Grooved Pegboard, in full cohorts
Time Frame: baseline, at 3 months, 6 months and 12 months
|
Neurocognitive testing will be performed at baseline, at three, six and twelve months follow-up using the Grooved Pegboard.
This added cognitive test is also chosen based on its proven sensitivity to measure change in neuro-oncology patients.
This test measures motor speed and dexterity and is an adjusted version of the Purdue Pegboard test.
The test consists out of plywood with 2 columns of 30 holes and a zinced bowl filled with metal pegs above each column.
Subjects are offered one minute to put as many pegs as possible into the holes.
The test has two different trials: dominant hand only and non-dominant hand only.
|
baseline, at 3 months, 6 months and 12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL5128302914
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Neoplasms
-
National Cancer Institute (NCI)CompletedBrain Cancer | Brain Neoplasm | Brain Tumor, PrimaryUnited States
-
Constantinos HadjipanayisNational Cancer Institute (NCI); NX PharmaGenWithdrawnGlioblastoma | Brain Cancer | Brain Tumors | Brain Tumor, Recurrent | Benign Neoplasms, Brain | Brain Neoplasms, Benign | Brain Neoplasms, Malignant | Brain Tumor, Primary | Intracranial Neoplasms | Neoplasms, Brain | Neoplasms, Intracranial | Primary Brain Neoplasms | Primary Malignant Brain Neoplasms | Primary Malignant... and other conditionsUnited States
-
Vanderbilt University Medical CenterUniversity of Alabama at Birmingham; Emory University; H. Lee Moffitt Cancer... and other collaboratorsTerminatedBrain Neoplasms, Benign | Brain Neoplasms, Malignant | Brain Neoplasm, PrimaryUnited States
-
BioNumerik Pharmaceuticals, Inc.Crown BioscienceCompletedBrain Neoplasms | Brain Tumors | Malignant Neoplasms, BrainUnited States
-
University of Erlangen-Nürnberg Medical SchoolNot yet recruitingBrain Tumor, Primary | Brain Tumor - MetastaticGermany
-
National Cancer Institute (NCI)TerminatedCentral Nervous System Neoplasms | Brain Cancer | Neoplasms, Brain | Primary Brain Neoplasms | Cancer of the BrainUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
Lawson Health Research InstituteCompletedBrain Tumor | Brain Neoplasm | Tumor, Brain | Neoplasm, Supratentorial | Tumor, SupratentorialCanada
-
University of NebraskaRecruitingPrimary Brain Tumor | Metastatic Brain TumorUnited States
-
Mayo ClinicRecruitingBrain Tumor | Brain Tumor Adult | Brain LesionUnited States
Clinical Trials on local SRT
-
Syneos HealthCompleted
-
Ruijin HospitalRecruiting
-
Sensus HealthcareCompletedNon-melanoma Skin CancerUnited States
-
University of KielMedical Laser Center Lübeck, Lübeck, Germany; Institute for Medical Informaties...CompletedCentral Serous Chorioretinopathy | Selective Retina TherapyGermany
-
Universitaire Ziekenhuizen KU LeuvenRecruitingBrain Metastases, AdultBelgium
-
Haaglanden Medical CentreRecruitingBrain MetastasesNetherlands
-
University of ArkansasTerminated
-
Sensus HealthcareUnknown
-
Sensus HealthcareUnknownKeloid ScarUnited States
-
University Hospital Schleswig-HolsteinSt Thomas; Medical Laser Center Lübeck, GermanyCompletedDiabetic Macular Edema